Intranasal absorption of Δ9-tetrahydrocannabinol and WIN55,212-2 mesylate in rats

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 65, Issue 2, 2007, Pages 247-252

  Valiveti, Satyanarayana ^a   Agu, Remigius U ^a   Hammell, Dana C ^a   Paudel, Kalpana S ^a   Caroline Earles, D ^a   Wermeling, Daniel P ^a,b   Stinchcomb, Audra L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Intranasal Therapeutics Inc   (United States)

Author keywords

9 Tetrahydrocannabinol; Cannabinoids; Ethanol; Nasal delivery; Pharmacokinetics; Propylene glycol

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ALCOHOL; MESYLIC ACID; PROPYLENE GLYCOL; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ADSORPTION; DRUG BIOAVAILABILITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; NOSE CAVITY;

ABSORPTION; ALGORITHMS; ANIMALS; ANTIEMETICS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; CHROMATOGRAPHY, LIQUID; ETHANOL; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; MORPHOLINES; NAPHTHALENES; NASAL MUCOSA; PERMEABILITY; POLYETHYLENE GLYCOLS; PROPYLENE GLYCOL; RATS; RATS, SPRAGUE-DAWLEY; SOLVENTS; TETRAHYDROCANNABINOL;

EID: 33845943071     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2006.08.009     Document Type: Article

References (22)

1. PDR Generics, Medical Economics, second ed., New Jersy, 1996, pp. 1083-1086.
2. Ohlsson A., Lindgren J.-E., Wahlen A., Agurell S., Hollister L.-E., and Gillespie H.-K. Plasma delta-9-tetrahydrocannabinol concentration and clinical effects after oral and intravenous administration and smoking. Clin. Pharmacol. Ther. 28 (1988) 409-416
3. Willaims S.-J., Hartley J.-P., and Graham J.-D. Bronchodilator effect of delta-9-THC administered by aerosol to asthmatic patients. Thorax 31 (1976) 720-723
4. Tashkin D.-P., Reiss S., Shapiro B.-J., Calvarese B., Olsen J.-L., and Lodge J.-W. Bronchial effects of aerosolized detla-9-THC in healthy and asthmatic patients. Am. Rev. Respir. Dis. 115 (1997) 57-65
5. Mattes R.-D., Engelman K., Shaw L.-M., and Elsohly M.-A. Cannabinoids and appetite stimulation. Pharmacol. Biochem. Behav. 49 (1994) 187-195
6. Jay W.-M., and Green K. Multiple drop study of topically applied 1% delta-9-THC in human eyes. Arch. Opthalmol. 101 (1983) 591-593
7. Arevalo-Martin A., Vela J.-M., Molina-Holgado E., Borrell J., and Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 23 (2003) 2511-2516
8. Gingold A.-R., and Bergasa N.-V. The cannabinoid agonist WIN55,212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sci. 73 (2003) 2741-2747
9. Zhang Q., Ma P., Isard M., Cole R.-B., Wang W., and Wang G. In vitro metabolism of R(±)-[2,3-dihydro-5-methyl-3- [(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4 benzoxazinyl]-(1- naphthalenyl) methanone mesylate, a cannabinoid receptor agonist. Drug Metab. Dispos. 30 (2002) 1077-1086
10. Corbo D.-C., Haung Y.-C., and Chein Y.-W. Nasal delivery of progestational steroids in overiectomized rabbits I, Progesterone-comparison of pharmacokinetics with intravenous and oral administration. Int. J. Pharm. 46 (1988) 133-140
11. Hussain A.-A., Hirai S., and Bawarshi R. Nasal absorption of propranolol in rats. J. Pharm. Sci. 68 (1979) 1196
12. Hussain A.-A., Hirai S., and Bawarshi R. Nasal absorption of propranolol from different dosage forms by rats and dogs. J. Pharm. Sci. 69 (1980) 1411
13. Pelser A., Muller D.-G., Plessis J.-D., Preez J.-L., and Goosen C. Comparative pharmacokinetic of single doses Doxylamine succinate following intranasal, oral and intravenous administration in rats. Biopharm. Drug Dispos. 23 (2002) 239-244
14. Hussain M.-A., and Aungst B.-J. Intranasal absorption of oxymphone. J. Pharm. Sci. 86 (1997) 975-976
15. Burstein A.-H., Modica R., Hatton M., Forrest A., and Gengo F.-M. Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration. J. Clin. Pharmacol. 37 (1997) 711-718
16. Edsbacker S., Anderson K.-E., and Ryrfeldt A. Nasal bioavailability and systemic effects of glucorticoid budesonide in man. Eur. J. Clin. Pharm. 29 (1985) 477-481
17. Li L., Gorukanti S., Choi Y.-M., and Kim K.-H. Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. Int. J. Pharm. 199 (2000) 65-76
18. A.-A. Hussain, L.-W. Dittert, A.-M. Qaisi, A. Traboulsi, Method for enhancement of delivery of THC by the administration of its prodrugs via the nasal route, New Millennium Pharmaceutical Research US Patent 6,380,175 (2001).
19. Hussain A.-A., Dakkuri A., and Itoh S. Nasal absorption of ondansetron in rats: an alternative route of drug delivery. Cancer Chemother. Pharmacol. 45 (2000) 432-434
20. Bechgaard E., Gizurarson S., and Hjortkjaer R.-K. Pharmacokinetic and pharmacodynamic response after intranasal administration of diazepam to rabbits. J. Pharm. Pharmacol. 49 (1997) 747-750
21. Lindhardt K., Olafsson D.-R., Gizurarson S., and Bechgaard E. Intranasal bioavailability of diazepam in sheep correlated to rabbit and man. Int. J. Pharm. 231 (2002) 67-72
22. Wall M.-E., Sadler B.-M., Brine D., Taylor H., and Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin. Pharmacol. Ther. 34 (1983) 352-363